Interspecific scaling of toxicity data.

ABSTRACT

This paper reexamines the scaling approaches used in cancer risk assessment and proposes a more precise body weight scaling factor. Two approaches are conventionally used in scaling exposure and dose from experimental animals to man body weight scaling (used by FDA) and surface area scaling (BW0.67--used by EPA). This paper reanalyzes the Freireich et al. (1966) study of the maximum tolerated dose (MTD) of 14 anticancer agents in mice, rats, dogs, monkeys, and humans, the dataset most commonly cited as justification for surface area extrapolation. This examination was augmented with an analysis of a similar dataset by Schein et al. (1970) of the MTD of 13 additional chemotherapy agents. The reanalysis shows that BW0.75 is a more appropriate scaling factor for the 27 direct-acting compounds in this dataset.